Johnson & Johnson said in a press release on Monday that it has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company that develops therapies for serious eye diseases. The deal calls for an upfront payment of $2.2 billion and potential additional regulatory and commercial milestone payments, which could increase the total value if the programmes reach certain development or sales goals. The deal includes a late-stage bispecific antibody for ophthalmology, which Johnson & Johnson described as having 'best-in-class potential.' Johnson & Johnson will also sign a separate development funding agreement with Blackstone Life Sciences. The acquisition will add Ollin's late-stage ophthalmology programme to Johnson & Johnson's pipeline. The announcement was issued from New Brunswick, New Jersey, on November 16, 2026.
Sources: Business Wire
To report an error in this article, write to corrections@venturistnews.com. Corrections log.
Nina Castell covers startups, funding rounds and acquisitions for Venturist. She writes from company announcements, filings and published reporting.
